No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Aurobindo Pharma Limited is a global pharmaceutical company specializing in the production of generic formulations and active pharmaceutical ingredients (APIs). Its operations span across India, the United States, Europe, and other international markets. The company's product portfolio includes a diverse range of finished dosage forms, such as oral medications, injectable drugs, and over-the-counter (OTC) remedies. Concurrently, it supplies APIs crucial for various therapeutic areas, supporting the development of products in biosimilars, dermatology, respiratory care, vaccines, peptides, oncology, hormone treatments, and sterile applications. Aurobindo also manufactures vital antiretroviral drugs, specifically designed to aid individuals and children affected by HIV. Additionally, it offers AuroZymes, a line of biocatalysts utilized across the pharmaceutical and chemical sectors. Furthermore, its AuroSource division provides comprehensive contract services for APIs, managing the full drug lifecycle from clinical development to manufacturing, particularly for penicillins, cephalosporins, and non-beta lactams. Established in 1986, the company maintains its headquarters in Hyderabad, India.
www.aurobindo.comNo one on the platform currently holds AUROPHARMA.BO.
No tracked institution reports a position in AUROPHARMA.BO as of their last filing.
No one on the platform has traded AUROPHARMA.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.6% | 21.0% | 26.8% | — | — | — |
| Rev. Growth % | 6.1% | 6.3% | ||||
| Profit Margin % | 10.4% | 10.3% | 12.7% | |||
| Free Cash Flow Margin % | 8.4% | 3.8% | 5.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $400.3B | +19.6% | $79.39 | $66.49–$96.94 | — | 23 |
| 2028 | $443.4B | +10.8% | $90.80 | $81.99–$108.45 | — | 23 |
| 2029 | $477.0B | +7.6% | $101.33 | $93.35–$120.94 | — | 10 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $17.26 | $17.86 | +3.5% |
| 2026-05-20 | $16.33 | $15.86 | -2.9% |
| 2026-02-09 | $15.94 | $15.67 | -1.7% |
| 2025-11-05 | $15.24 | $14.61 | -4.1% |
| 2025-08-03 | $16.68 | $14.20 | -14.9% |
| 2025-05-26 | $17.57 | $15.56 | -11.4% |
| 2025-02-07 | $15.54 | $14.56 | -6.3% |
| 2024-11-08 | $16.05 | $14.00 | -12.8% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AUROPHARMA.BOAurobindo Pharma Limited | $1669.90 | -0.33% | $960.5B | — |
| ABBOTINDIA.BOAbbott India Limited | $25755.00 | +0.72% | $547.8B | — |
| ABBOTINDIA.NSAbbott India Limited | $25835.00 | +1.12% | $549.0B | — |
| ALKEM.BOAlkem Laboratories Limited | $5154.75 | +1.28% | $615.4B | — |
| ALKEM.NSAlkem Laboratories Limited |
| $5213.00 |
| +2.47% |
| $623.3B |
| — |
| GLENMARK.BOGlenmark Pharmaceuticals Limited | $2407.10 | -0.41% | $695.3B | — |
| GLENMARK.NSGlenmark Pharmaceuticals Limited | $2400.60 | -0.77% | $677.5B | — |
Source: Financial Modeling Prep · peers by sector/industry